TrialLeukemia2026

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Andreas Burchert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.